论文部分内容阅读
目的:探讨类肝素酶(Heparanase)成为一种预判肾上腺恶性嗜铬细胞瘤指标的可能性。方法:选取经手术治疗且具有完整的临床、病理和随访资料的肾上腺嗜铬细胞瘤患者的存档石蜡标本27例,其中良性嗜铬细胞瘤10例(良性组),恶性嗜铬细胞瘤17例(恶性组)。另取5例因良性肾疾患行肾切除时获取的同侧正常肾上腺组织作为对照组。采用免疫组织化学技术检测良、恶性嗜铬细胞瘤及正常肾上腺髓质组织中Heparanase-1的表达情况。结果:Heparanase-1在肾上腺恶性嗜铬细胞瘤中表达最高(76.5%),在肾上腺良性嗜铬细胞瘤中表达较低(30.0%),在正常肾上腺髓质组织中无表达,恶性组与良性组及恶性组与正常组之间Heparanase-1的表达差异有统计学意义(P<0.05)。结论:Heparanase-1有望成为预判肾上腺恶性嗜铬细胞瘤的一种指标。
Objective: To investigate the possibility of heparanase as a predictor of adrenal malignant pheochromocytoma. METHODS: Totally 27 paraffin-embedded specimens of adrenal pheochromocytoma patients who underwent surgery and had complete clinical, pathological and follow-up data were selected. Among them, 10 were benign pheochromocytoma (benign group), 17 were malignant pheochromocytoma (Malignant group). Another 5 cases of nephrectomy due to benign renal disease obtained ipsilateral normal adrenal tissue as a control group. Immunohistochemistry was used to detect the expression of Heparanase-1 in benign and malignant pheochromocytomas and normal adrenal medulla. Results: Heparanase-1 had the highest expression in adrenal malignant pheochromocytoma (76.5%), lower expression in benign adrenal pheochromocytoma (30.0%), no expression in normal adrenal medulla, malignant group and benign The difference of Heparanase-1 expression between the malignant group and the normal group was statistically significant (P <0.05). Conclusion: Heparanase-1 is expected to be a predictor of adrenal malignant pheochromocytoma.